AnorMED to focus on Mozobil development

By Elaine Rigoli

Tampa, Fla., June 13 - AnorMED said its new corporate strategy is designed to transform the company from a research focus into a successful, fully integrated biopharmaceutical company built around the timely development and commercialization of Mozobil.

Mozobil is now being evaluated in two phase 3 clinical studies after demonstrating the potential to help cancer patients successfully undergo stem cell transplants in phase 2 clinical studies.

This strategic direction was selected by the new board of directors and management in the belief that the best way to maximize near-term and long-term shareholder value is to complete the final stages of Mozobil development in North America and Europe independent of strategic partners, officials said.

The company said it will then implement a global commercial strategy involving the appropriate combination of direct marketing by AnorMED and arrangements with local distributors and regional partners.

The important near-term goal will be to complete the current phase 3 studies and announce data from both studies in patients with multiple myeloma and non-Hodgkin's lymphoma by the second quarter of calendar 2007.

Assuming successful results from these two studies, the company said it would expect to complete filings for marketing approval in the United States, Canada and Europe in 2007 and 2008.

AnorMED is a chemistry-based biopharmaceutical company based in Langley, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.